Stereotaxis , Inc. (NYSE: NYSE:STXS) discussed its second quarter 2024 financial results, revealing an operating loss of $6 million and a net loss of $5.8 million, which is a slight increase from the previous year's figures. CEO David Fischel expressed confidence in the company's future, citing a robust pipeline and strategic innovations.
Despite the losses, the company is optimistic about the second half of the year, expecting over $14 million in revenue. Stereotaxis expects to improve its financial performance with the launch of its new products, including the MAGiC catheter and the GenesisX system, and has completed the acquisition of Access Point Technologies (APT), which is already yielding sales synergies.
Key Takeaways
- Stereotaxis reported an operating loss of $6 million and a net loss of $5.8 million for Q2 2024.
- CEO David Fischel anticipates a stronger second half with significant progress in reducing the Genesis system backlog and active late-stage sales pipeline.
- The company has submitted regulatory applications for its MAGiC catheter in Europe and the U.S., with expected approvals to follow.
- Stereotaxis completed the APT acquisition, which has begun to show sales synergy.
- Financial outlook for H2 is positive, with expected revenue of over $14 million, a strong balance sheet, and no debt.
Company Outlook
- Stereotaxis is focusing on strategic innovations including GenesisX, MAGiC, and the APT acquisition to drive future growth.
- The company plans to launch the GenesisX system in 2025 following regulatory clearance.
- Revenue is projected to increase in H2 2024, with an expected total over $14 million.
Bearish Highlights
- The company experienced an increase in operating and net losses compared to the previous year.
- Financial performance in the first half was disappointing, with losses exceeding the prior year's.
Bullish Highlights
- The GenesisX robotic platform and MAGiC catheter are nearing commercialization, which could stimulate revenue growth.
- The acquisition of APT has already led to positive feedback and sales synergies.
- The company maintains a strong balance sheet with $13 million in cash and no debt planned.
Misses
- Initial H1 performance fell short of expectations, showing an increase in losses year-over-year.
- Details on the pricing strategy and margin profile for GenesisX were not disclosed.
Q&A Highlights
- The financial model will focus on placements with disposable commitments to leverage recurring revenue.
- Initial data from the MAGiC-FEST study has been submitted for regulatory approval.
- The company can manufacture one system per month and is prepared to scale up production as needed.
- Despite some hospitals waiting for GenesisX, the company has enough backlog and pipeline clarity to sustain operations.
Stereotaxis, Inc. remains optimistic despite the challenges faced in the Chinese market and broader macroeconomic headwinds. The company is committed to strengthening its market position through strategic innovation and robust sales pipelines in China, Europe, and the U.S. As the company awaits regulatory approvals for its innovative products, it is poised to potentially improve its financial performance in the latter half of the year. Stereotaxis is focused on delivering value to its shareholders and is looking forward to the next quarter with anticipation.
InvestingPro Insights
Stereotaxis, Inc. (NYSE: STXS) continues to navigate a challenging financial landscape, as reflected in the latest data from InvestingPro. With a market capitalization of $150.5 million and a Price / Book ratio of 10.33 as of Q1 2024, the company is trading at a valuation that suggests investors are paying a premium for its book value. This high Price / Book multiple could be attributed to the market's anticipation of the company's strategic initiatives, including the GenesisX system and the MAGiC catheter, potentially leading to future growth.
The company's stock price movements have been notably volatile, which might be a point of consideration for investors seeking stability. InvestingPro Tips also indicate that Stereotaxis is not expected to turn a profit this year, aligning with the company's reported operating and net losses for Q2 2024. However, the company's liquid assets surpass its short-term obligations, suggesting that it has enough liquidity to meet its current liabilities.
Investors may also find it relevant that Stereotaxis does not pay dividends, which could influence the investment decisions of those prioritizing income-generating stocks. For more detailed analysis and additional InvestingPro Tips on Stereotaxis, investors can visit https://www.investing.com/pro/STXS, where 6 more tips are available to provide a comprehensive understanding of the company's financial health and future prospects.
Full transcript - Stereotaxis Inc (STXS) Q2 2024:
Operator: Good afternoon, and welcome to the Stereotaxis, Inc. Second Quarter 2024 Earnings Conference Call. Certain statements during the call and question-and-answer period to follow may relate to future events, expectations and, as such, constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the company in the future to be materially different from the statements that the company's executives make today. These risks are described in detail in our public filings with the Securities and Exchange Commission, including our latest periodic report on Form 10-K or 10-Q. We assume no duty to update these statements. [Operator Instructions] As a reminder, today's call is being recorded. It is now my pleasure to turn the floor over to your host, David Fischel, Chairman and CEO of Stereotaxis.
David Fischel: Thank you, operator, and good afternoon, everyone. We have made significant progress this quarter on several key aspects of our strategic transformation. I want to spend the majority of today's call reviewing those advances and how we are establishing a solid foundation upon which to build a substantial and successful company. Before getting to that, though, I want to address head on our commercial results and financial position. I recognize the quarterly numbers were disappointing. Our results for the first half of this year were significantly impacted by reduced capital revenue. These results do not reflect a steady state reality. We are confident in a significantly stronger second half of this year from both a revenue and cash flow perspective. Let me briefly address the weak first half and share the source of our optimism in an improved second half. Despite our significant backlog of Genesis orders, the timing of multiple hospital projects and associated system shipments became elongated, leading to minimal capital revenue in the first and second quarters. Capital sales are inherently lumpy, and the first half was far below our normalized level. Our visibility into system shipments during this third quarter and the remainder of this year gives us high confidence in significantly higher revenue recognition and cash flow. There are currently two Genesis systems in transit to European customers as we speak, with revenue recognition taking place upon delivery of those systems. There's one additional system ready to be shipped within the coming days, and we have signed purchase orders with down payments for two additional systems planned to be shipped before year-end. One of those has a contractual requirement dictated by a tender to deliver the system in the fourth quarter. The three Genesis systems currently being shipped will generate $5.5 million in revenue recognition upon delivery. The two additional systems I noted would add an additional $3 million. There remains a backlog of ordered systems beyond these 5, which are still waiting on hospitals to be ready for delivery and will likely take longer but could accelerate. We also have an active late-stage sales pipeline in all three of our key geographies, and we expect additional purchase orders for Genesis systems in the coming months. Our cash utilization in the first half of this year was significantly impacted by the weakness we had in capital sales. We can model the substantial cash receipts due with delivery of the systems I just referenced, and based on those, our best assessment is to end this year with approximately $13 million in cash and no debt. While it would be nice to have a more substantial balance sheet, we feel confident in our upcoming milestones and the incremental revenue and profit they will deliver. Our existing balance sheet allows us to reach key milestones, commercialize our new innovation and profitably grow our business. Shifting now to the progress I mentioned on our strategic innovation efforts. On the past several calls, I reviewed the full spectrum of strategic efforts we're advancing in parallel and how those are establishing a solid foundation upon which to build a substantial and successful company. I'll focus today's call going in more depth on three of the most impactful areas for future commercial success for which we have made significant progress in the last quarter: GenesisX, MAGiC and the APT acquisition. Let me start with GenesisX. In a press release this afternoon, we were excited to introduce GenesisX publicly and to share the accomplishment of key regulatory milestones: obtaining CE mark for the system in Europe and submitting a 510(k) application with FDA. GenesisX is an entirely new robotic platform, the third for Stereotaxis after Niobe, which was released in 2003; and Genesis in 2020. It incorporates newly designed magnets that are significantly smaller than before, a particularly innovative robotic base with built-in magnetic shielding and more streamlined, distributed and sophisticated electronics throughout the system. GenesisX builds upon the well-established proprietary technology Stereotaxis has pioneered and mastered: robotic magnetic navigation. It's designed with the same uncompromising eye towards clinical performance, robust real-world reliability and intuitive ease of use. It retains the speed and immediate responsiveness of Genesis, which has been well received by our physician users. What is special about GenesisX is that we have made robotic magnetic navigation available in a form factor that supports broad accessibility and commercial scalability. As mentioned in the past the challenges of translating physician interest in robotics into adoption and commercial growth, we operate in a huge and highly attractive market, in which we hold less than 1% market share despite our established clinical benefits and unique differentiation. We have had hundreds of physicians express genuine interest in our technology since launching Genesis. Over 95% never end up getting the robot. The single largest impediment is the reliance on hospital construction and the long extended timeline that creates, along with the complexity of translating physician clinical interest into full organizational movement at the hospital. Our Niobe and Genesis Systems require architectural planning and construction to accommodate their installation. Preparing an operating room to accommodate a system entails significant structural modification, including the installation of thousands of pounds of magnetic shielding in the walls, reinforcement of the floor, high-power electrical work and extensive cabling through conduits between the operating room, control room and cabin room. This adds cost for the hospital, but more importantly, turns a purchase into a long complex process. The complexity of coordinating site planners, architects and contractors leads many potential deals to stall or fizzle away. In the fortunate cases where a robotic sale comes to fruition, we and the interested customers work through a multiyear sales cycle before translating interest into actual use. GenesisX allows us to transition from a construction model to a placement model. The system's smaller magnets are stored in magnetic shielding built into the robotic base itself, negating the need for the shielding otherwise installed in the walls of operating rooms. GenesisX requires no structural anchoring through the floor and operates using standard 120- or 230-volt power outlets, the same that was used for your laptop or iPhone. A single thin fiber is routed from each robot to the system cabinet, with 96% and 99% reduced volume compared to the cable bundles routed to the cabinets of Genesis or Niobe. The cabinet of GenesisX is itself 80% smaller than the cabinet of Genesis and can fit under a table in the operating or control room rather than in a separate dedicated cabinet room. We expect to be able to install a GenesisX system over the weekend and for it to be a viable solution for the majority of labs. Accessibility for customers is of primary importance. Also important is ensuring scalability of manufacturing and operations. We designed GenesisX to support improved supply chain, manufacturing and installation operations. The two sides of the GenesisX robot are identical to each other rather than mirrors of each other like in Genesis or Niobe. This substantially reduces the number of unique components in GenesisX, improving supply chain management and simplifying assembly and testing. We're reducing the shipping requirements from 12 big crates per Genesis system to six crates with GenesisX. The system will be shipped nearly fully assembled, with the magnets already installed, aligned for rapid installation with less time spent on site. Simplifying site planning, shipping and installation allows us to scale our business without the strains and investment of scaling those organizational capabilities. Transitioning from a construction model to a placement model may sound minor, but it is a world of difference. Being freed from complex planning or construction enables a more streamlined and rapid translation of clinical interest into clinical use. It allows us to confidently offer alternative financial models for adoption. While Genesis X will demand a premium over Genesis, it will be available for purchase, operating lease or for placement with disposable commitment. As we look at the EP field and then the broader universe of endovascular surgery, there's easily room for thousands of robotic magnetic navigation systems. GenesisX comes in an architecture that allows us to envision realistically scaling a business that can positively transform our large markets. Obtaining CE mark and filing our 510(k) submission are major milestones. We look forward to supporting the FDA review of GenesisX, and it is reasonable to expect regulatory clearance by year-end. There is some additional work to be done prior to full commercial launch. First and foremost, and I'll discuss this in more detail in a moment, we are advancing towards regulatory approval of the compatible MAGiC ablation catheter, which is necessary to use GenesisX. In parallel to the regulatory efforts, we will use the coming months to enhance compatibility of GenesisX with various X-rays, prepare our supply chain in manufacturing, installation and commercial processes and demonstrate real-world use of the system. We expect the full launch of the system and initial significant adoption of GenesisX in 2025. This segues into the second critical puzzle piece in our new foundational product ecosystem, our proprietary robotically-navigated ablation catheter, MAGiC. As we have discussed in the past, we've been hampered clinically, commercially and strategically by our dependence on the J&J catheter used in every robotic procedure. That ablation catheter is a 20-year-old design with significant room for improvement and clinical performance. MAGiC incorporates many design enhancements that we believe will improve the experience of our physician users and the outcomes of their patients, including increased stability, more intuitive navigation, better information from the ablation tip and reduced fluid load. Commercially, Stereotaxis receives no revenue or economic value from J&J sales of the current catheter, robbing us of the vast majority of disposable revenue in every robotic procedure. While we have a razor-razor blade business model, we've been giving up 80% of the razor blade. MAGiC will fairly rapidly allow us to multiply our disposable revenue and gross profit from every robotic procedure. That improved revenue model allows us to profitably scale a commercial organization in a much more robust fashion. Lastly, strategically, our dependence on J&J's catheter has limited our ability to collaborate and develop a healthy ecosystem around our robot. You've already seen some of the collaborations that have come from the realization that MAGiC is approaching commercialization, and additional opportunities are becoming increasingly possible. The development, clinical and regulatory process for an ablation catheter is an arduous path. We have invested many years of effort and millions of dollars getting our proprietary MAGiC catheter to the cusp of commercialization. Earlier this year, we announced submission of a CE application to the EU notified body and the submission of a PMA application to the FDA for MAGiC. We have made meaningful progress on both submissions. The European regulatory review consists of three distinct sync sections: a clinical, technical and microbiology assessment. Since our last call, we successfully completed both the clinical and technical reviews by the EU notified body, with receipt of written confirmation of having met all requirements in those two sections. We are still waiting to receive the microbiology questions, but have been advised that they should arise momentarily and hope to similarly successfully complete that section in the coming weeks. With receipt of CE mark, we will initiate a full launch of MAGiC in Europe, benefiting from the clinical experience and awareness generated by the ongoing MAGIC clinical study. In the U.S., it's not as simple to describe the regulatory review process, but there has also been significant progress in recent weeks. We've had continuous dialogue with FDA since the PMA submission and are very appreciative of the collaborative and thoughtful discussions and guidance. The PMA submission is being refined with that guidance, and the ongoing dialogue supports our expectation of achieving an initial regulatory approval, leveraging the existing data being generated in the European MAGiC study, with a clear plan for subsequent post-approval studies in the U.S. We appreciate the responsiveness and collaborative nature of these discussions and believe they are reflective of a shared appreciation for the importance of ensuring MAGiC becomes available for patients and physicians who depend on it. The final topic that I want to cover on this call and which will have significant importance to our trajectory is acquisition of Access Point Technologies. We announced the agreement to acquire APT on our call in May and closed the acquisition just over a week ago at the end of July. This was Stereotaxis' first acquisition ever, reflective of our selectivity and focus. The acquisition was opportunistic and pursued in a financially prudent fashion, for what is most important for significant value creation is the strong synergistic and strategic rationale for the acquisition. We were fortunate to announce the acquisition immediately before the largest conference in our field: HRS. APT's products were included in the Stereotaxis group, and both teams worked together at the conference. We had entered into this agreement cognizant of the natural sales synergy. APT had minimal U.S. revenue from differentiated high quality diagnostic EP catheters, a consequence of having no dedicated sales team. Stereotaxis has over 20 people in the field across the U.S. who are particularly skilled and focused on enabling and improving the treatment of the most complex arrhythmias. APT's products and Stereotaxis' commercial team align beautifully from a messaging perspective and from both the physician and procedure focus. These sales synergies were at full display at HRS. The Stereotaxis commercial team picked up on the products quickly and were enthusiastic about the new opportunity. Physician customers of Stereotaxis were very pleased and supportive of the acquisition strategy, and while the vast majority had never before been exposed to APT's products, they viewed the catheters as attractive and relevant. Following HRS, we did a more formal training of our entire team, began the process of establishing commercial plans and started engagement in the field. We already have over a dozen physicians and hospitals newly exposed to APT that have tried the catheters or have begun value analysis committee submissions at their hospitals to be able to purchase the catheters. APT's U.S. capital revenue in July was approximately 50% higher than the average monthly revenue in the first half of this year or 2023. Working through VAC submissions and building commercial momentum is more like a snowball than flipping a light switch, but we are already seeing an initial impact and believe we can grow these products substantially in the coming months. The sales synergy also works both ways. APT's catheters contribute incremental revenue in the practices our team already calls upon, and in reverse, these catheters serves as a door opener at centers focused on complex arrhythmias to pave the path for the adoption of robotics. Our primary motivation for acquiring APT was not the opportunistic nature of the situation nor the sales synergy, but rather the strategic value of having in-house catheter development and manufacturing expertise. APT's team, expertise and capabilities will significantly amplify and accelerate Stereotaxis' next wave of innovation efforts as we look to develop a broader family of interventional devices that are navigated by our robots within electrophysiology and across a range of endovascular procedures. There are three specific areas of focus I want to touch upon. First, a broader family of robotically-steered catheters to complement MAGiC in EP; second, an emerging and tangible multi-life PFA strategy; and third, our expansion into new clinical applications. On the first topic, the emergence of high-density mapping has been a significant change to the EP field over the past decade. Stereotaxis has never developed a robotically-steered high-density mapping catheter, and so in a majority of our procedures, the physician navigates a manual mapping catheter by hand, separate from the robotically-steered ablation catheter. The workflow is viable, but not ideal, and there has been strong physician interest, value from a procedural workflow perspective and clinical merit for robotically-steered dedicated mapping catheter. We had already begun developing such a catheter prior to the acquisition and are now accelerating that process, with the catheter design complete and production of hundreds of units taking place for formal regulatory testing. We expect the catheter to receive regulatory approval within a year and to be highly synergistic with MAGiC. From a commercial perspective, if the introduction of MAGIC increases our expected revenue per procedure three to fourfold, the addition of a mapping catheter leads to a five to sixfold increase in revenue per procedure. Those numbers sound observe given our current vantage point, but reflect the normal revenue model and pricing of any other participant in the EP field. They shine light on to the miss opportunity embedded into our current product ecosystem and the structural transformation at play. On to the second topic, PFA. Pulsed field ablation or electroporation is a new energy source available for cardiac ablation procedures as an alternative to radio frequency or cryo. The first PFA catheters just entered the field and are already on track for over a couple of billion dollars in annual revenue, partially through conversion of procedures to the other energy sources, but principally through market expansion. Stereotaxis has been largely protected from the effects of PFA in our existing procedures, but we recognize the impact it is having in the field and the importance of offering choice and a broader ecosystem of catheter options with our robot. I can't yet fully share our activities in PFA, but I can shed some color on our efforts. We have three distinct more advanced PFA opportunities being advanced in tandem. One leverages the MAGiC catheter and the other two use unique PFA catheters. Two are done in collaboration with partners and one is fully owned technology we acquired with APT that is being advanced in collaboration with the Mayo Clinic. We've had an accelerating pace of preclinical PFA studies in recent months and have line of sight towards first-in-human studies for at least two of these opportunities within the next six to 12 months. One is likely to even become commercially available in Europe in 2025. Our collaboration with the Mayo Clinic is exciting, and I had the opportunity to visit them last month. The PFA catheter they designed with APT is particularly differentiated, addressing some of the clinical challenges with efficacy, durability and patient safety that are starting to emerge with commercial single-shot PFA catheters. After significant effort, we are starting to see green shoots emerge, with multiple shots on goal for clinically meaningful technologically differentiated and commercially impactful PFA catheters. The last topic, the expansion of our robotic technology into a broader set of applications, is something we've discussed previously. We are in the late stages of developing robotically steered guidewires and guide catheters that expand the value of our robot into several large fields, such as neuro intervention, interventional cardiology and interventional radiology. These are advancing on track for regulatory submission within the next six months and the guide catheter is being developed with APT. Having skilled in-house catheter design and manufacturing expertise will be particularly beneficial as we explore innovative ideas shared by physicians for ways our technology can add value in these new indications. It accelerates dramatically the time to an initial prototype and the ability to iterate with feedback. While the first guidewire and guide catheter sold out for a strong initial offering as we begin to address the broad endovascular surgery field, the in-house capabilities of APT are of great strategic value to accelerating and improving our expansion. We are pleased with the significant progress we are making in establishing a healthy foundation for Stereotaxis upon which to build a substantial, high-growth, profitable business. This was a busy quarter for us, particularly in these three key areas, but also in our other efforts, including regulatory efforts in China, and the Synchrony and Sync telesurgery platform. We see the puzzle pieces falling into place in each of our three key geographies: the U.S., Europe and China. We have opportunity for a full ecosystem coming together and driving breakout growth. The opportunity in any individual geography can dwarf our current entire business. I'll hand the call over to Kim now to discuss our financial results. Kim?
Kimberly Peery: Thank you, David, and good afternoon, everyone. Revenue for the second quarter of 2024 totaled $4.5 million compared to $7.9 million in the prior year second quarter. System revenue for the second quarter was $0.2 million, and recurring revenue was $4.3 million compared to $3.3 million and $4.6 million in the prior year second quarter. The majority of the revenue decline in the current quarter is driven by timing of system deliveries delayed by elongated customer construction projects. System revenue in the current quarter reflects minimal revenue recognized on system installations compared to more substantial system revenue recognized in the prior year quarter from system delivery. System revenue is inherently uneven from period to period, and the performance in the quarter is not reflective of our expectations for the balance of the year. We maintain system backlog of $15.3 million as of the end of the second quarter. Gross margin for the second quarter of 2024 was 74% of revenue. Recurring revenue gross margin was 76%, and system gross margin was 22%. Operating expenses in the quarter of $9.3 million included $2.5 million in noncash stock compensation expense. Excluding noncash stock compensation expense, adjusted operating expenses were $6.8 million, comparable to prior year adjusted operating expenses of $6.9 million. Operating expenses in the quarter were impacted by higher acquisition-related legal costs and regulatory-related activities counteracted by the reversal of a historical approved liability. Operating loss and net loss for the second quarter of 2024 were $6 million and $5.8 million compared to $5.3 million and $5 million in the previous year. Adjusted operating loss and adjusted net loss for the quarter, excluding noncash stock compensation expense, were $3.5 million and $3.3 million compared to $2.7 million and $2.4 million in the previous year. Negative free cash flow for the second quarter was $3.1 million. Our financial statements for the second quarter do not reflect any consolidation or impact from the APT acquisition beyond legal expenses incurred during the acquisition process. We are consolidating APT's results starting August 1. Our third quarter financial results will therefore include two months of APT results. At June 30, we had cash and cash equivalents of $15.2 million and no debt. I will now hand the call back to David.
David Fischel: Thank you, Kim. As mentioned previously, we continue to focus on realizing our strategic transformation while maintaining commercial momentum in preserving financial strength. Substantial value creation is ultimately predicated on establishing the right foundations for the company upon which we can profitably grow orders of magnitude larger. While our short-term results had a minimal impact on our long-term value, we recognize the quarterly numbers are disappointing. Our visibility into the second half of this year gives us high confidence in significantly improved performance compared to the first half of the year. We expect greater than $14 million in revenue in the second half of this year, with stable recurring revenue and the minimum revenue from the Genesis systems currently being shipped. We expect likely upside to that minimum expectation, with full year revenue approximately equal to the previous year. These expectations do not incorporate contributions of revenue from APT or potential revenue from the launch of GenesisX and MAGiC. We are cognizant of the importance of protecting our balance sheet, protecting shareholders from unnecessary dilution and managing Stereotaxis in a financially prudent fashion. We expect to end this year with $13 million in cash and no debt. We view our existing balance sheet as allowing us to reach key milestones, commercialize our new innovation and profitably grow our business. We have no intention of diluting shareholders at current valuation levels, and will be thoughtful in how we manage our financial position and protect shareholder value. Operator, can you please open the line to Q&A?
Operator: [Operator Instructions] Our first question comes from the line of Adam Maeder with Piper Sandler. Please go ahead.
Adam Maeder: Hi. Good afternoon, David and Kim. Thank you for taking the questions, and congrats on the approval for X in Europe. I guess a couple of questions from me. The first one would be on the MAGiC catheter and wanted to, I guess, better understand the CE mark commentary there. So it sounds like you're getting pretty close. I think I heard you use the verbiage, hope to complete the microbiology part of the submission or review shortly and then you'll kind of be off to the races, and I also heard there's no assumed contribution in the guidance from MAGiC. So David, maybe you can kind of help square that up for us? Once you have CE mark approval in hand for the MAGiC catheter, how aggressively will you launch into the marketplace? That's my first question, and I have a follow-up or two. Thanks.
David Fischel: Sure. Thanks, Adam. Good afternoon. So you understood our regulatory progress and status correctly in Europe. There are three areas of review that the notified body does as part of the review of the submission, and two out of those three including the most important one for us, which was the clinical area, which a year ago prompted us to have to do the clinical study, we passed successfully. So those kind of are buttoned up and final kind of success marks. The microbiology question, we have not yet received. And so we're waiting to receive. We've been told that they should come any day. We thought that they would already have arrived last week, and we're waiting with bated breath for those questions. We never know exactly what to expect whether those are going to be few questions or many questions, whether there's going to be any questions that require more significant effort to respond to or whether they're largely administrative responses to them. So as we get that, we're obviously going to have a much better feeling for the status. About a year ago or a little bit over a year ago when we went through the review process, at the time, there were essentially no material questions on the microbiology side of things when they asked us to do a clinical study because they couldn't pass us on the clinical side. So we're hopeful that we'll have something similar like that when we get the first round of questions, but obviously, we have to wait to see those questions. And once the microbiology questions are received, we respond to them. Let's kind of hope that, that goes smoothly and we get kind of also written confirmation that we passed the microbiology review. Then really, there's no additional review. There's I think some administrative effort just to get the final signatures and kind of the sign off from them, but that's the last part, substantive, to the whole process. We have benefited in some ways through this time that we're working through the regulatory process in preparing for a commercial launch. And we have about 35 or so hospital accounts in Europe. The knowledge of the human experience in the clinical trial has spread organically from the physician users in Copenhagen Vilnius, where the clinical trial is taking place naturally to many of the other physician users there. And so I think there's good awareness of the performance of MAGiC and how it has improved the situation. There's also been the benefit of EnSite X integration with Stereotaxis having more and more time to become adopted across multiple sites there. And so that also sets things up well for MAGiC. And so we're going to kind of do a full launch of MAGiC as we have regulatory approval. I think I've spoken in the past that there are certain geographies where there are kind of more local tender requirements beyond the CE mark approval, so you have to wait until you receive CE mark before you can go through some of those tenders. That will slow down adoption in some of the accounts, as you walk through those administrative items. But generally, we plan to do a full launch.
Adam Maeder: That's very helpful color, David. Thank you for all that. And for the follow-up, just a multipart question on the GenesisX system. And I guess one part is just trying to better understand the pricing strategy and margin profile of the system. And then I also heard you, I think, reference different selling models there. I think I heard outright capital purchase, operating lease and volume-based agreements. So I would love for you to kind of flesh those out for us. And then just any color in terms of speed of launch. I mean it certainly sounds like 2025 is really when you're going to kind of be making a bigger push in Europe with X and, I guess, the U.S., for that matter, but I would love just to hear a little bit more about kind of the initial launch plans. Thanks so much for taking the questions.
David Fischel: Sure. Thanks for the good question. So we -- obviously, we can't launch GenesisX until we get MAGiC approved both in Europe and the U.S. And so that is a little bit holding us back at this point from trying to launch the system or even announce it in a more complete way. We're going to use the remainder of this year to get those approvals, to prepare ourselves for a full launch. And I view some of the larger conferences next year in Europe and the U.S. as the ideal setting in which to launch GenesisX. In many ways, this is not just a product launch. This is reframing, reintroducing Stereotaxis' to the community, to our EP community, in a way that breaks down many of their historical misperceptions or perceptions on the technology. And so kind of we view kind of doing the good launch of the technology when we're able to do so as kind of very important, and we plan to make a lot more noise than we're doing today given that today, again, we're not really at the point of launching the technology fully. And from a pricing margin, revenue model or sales model perspective, I don't want to give too much detail at this point. There will be an opportunity in the future to provide more details. So I'll just kind of talk philosophically how we're approaching it. And again, when we do a full launch, there'll be opportunities to speak kind of with more details. And philosophically, GenesisX will command a premium over Genesis. It is the latest technology. It saves the hospital significant amounts of investment that they would otherwise make in the system. And so I think that's kind of a warranted natural move for us. In terms of the complexity of manufacturing and installation, this is still a highly sophisticated device with many expensive components. This is -- we're building complex, very high-quality robotic technology. We've done various smart things, like I mentioned in the prepared remarks, to make manufacturing and installation simpler. And so generally, I would expect -- I think it'd be fair for you to expect that we would benefit from those types of moves. And when it comes to the commercial models, we plan to -- the value of a robot remains the value of a robot. And so we don't plan to discount the value of the robot. You can capture that value, though, in different ways from a cash flow perspective, from a kind of a commercial model perspective that you present to the customer. The most natural way, the way that Stereotaxis has experienced this entire existence, is selling a system, right? And so we'll obviously continue to sell a system like we do currently with Genesis. We'll sell GenesisX. It will be at a premium. But obviously, the hospital will benefit from reduced costs in terms of architects and contractors. We will also offer two other models that will, again, retain the same value of the robot, but offer the robot through different mechanisms. One will be a leasing model and the other will be a placement of the robot with a minimum of disposable purchase commitment. And so those are both viable models. We're not innovating completely new things. There's a very, very large company that have tread this path before us, and so we're obviously learning from that experience. If you look at kind of, obviously, the leader in the robotic surgical field, not in our space at all, not a competitor, but the leader in surgical robotics, they, by now, the majority of their system placements in any given year are leases and placements with disposable commitments rather than sales outright. And so I think that's a model that also hospitals are very comfortable with. And from a financial perspective for us, given the significant recurring revenue model that is starting to be built around our business, right, the razor blade model that is being enhanced with the MAGiC catheter, with the high-density mapping catheter I mentioned, with the devices that can allow the same robot to be used in other applications, it becomes very financially reasonable to offer those alternative models and to deal with the cash flow and not to have kind of -- not to have any particular challenges from a working capital perspective.
Adam Maeder: Thanks for all the color. David, I'll hop back in queue.
David Fischel: Thank you.
Operator: Our next question comes from the line of Josh Jennings with TD Cowen. Please go ahead.
Josh Jennings: Hi. Good afternoon. Thanks for taking questions. Great to see the GenesisX CE mark approval in hand. I wanted to ask David about the MAGiC-FEST study, and I think we saw a glimpse of the first 40 patients at HRS. But maybe just anything else you can share just on the results from that study? And on top of that, is the dataset that's submitted to CE mark, that will be submitted for CE mark approval, already has been actually, as you disclosed, the same dataset that you can submit for -- in the U.S. to the FDA for the PMA filing? Or is there going to be more patients that have been enrolled and where longer follow-up is required?
David Fischel: Sure. Good afternoon. Josh, thanks for that question. So like you mentioned, the MAGiC-FEST study is the clinical human study that's taking place at two centers in Europe. They used MAGiC over the last several months from the beginning of this year in treating a broad range of arrhythmia patients. Over that time, we submitted initial data at the end of February on the patients that had enrolled up to that point with our CE mark submission, and we included it in the PMA submission as well. Those sites have continued to enroll patients. And while initially, the study was designed with a maximum of 30 patients per site, we did expand that upper bound. And so they're continuing to enroll patients as we speak. And we're overall very pleased with the performance of MAGiC. So the physicians did present some of the data at HRS, so that's available through them. They're working together on -- they submitted for publication additional data beyond that. I don't -- it's not my place to share exact results, given that they're trying to get it published. So I think I'll kind of -- I'll leave that for them to publish. But overall, we're delighted with the performance of MAGiC. It's definitely good catheter. It's working in humans. It's treating patients on a regular basis, and the clinical improvements and performance improvements versus the THERMOCOOL RMT catheter of J&J are real and are being seen in the real world. And when we look at FDA, I mentioned in the prepared remarks kind of the regular discussions we're having with FDA, and a lot of that is tied towards what would be the most useful data for FDA to see at this point to be able to provide regulatory approval in the U.S., leveraging the data that's coming out of Europe and what data and what study designs would be useful for a post-approval study in the U.S. both to corroborate the data through a U.S. study and to expand label, expand indications in the U.S. to kind of have a broader label. And so that's been -- the majority of the discussions have been around that topic. There is some, let's call it, focusing of the types of patients, types of data that's being collected in Europe based off of the feedback that's being received from FDA and those discussions with FDA. So there's continuous enrollment in Europe. And I think, again, that we have a good kind of shot and good alignment in terms of that data, assuming it continues to enroll well, will be good for our FDA submission.
Josh Jennings: Excellent. Thanks for that. And just on the MAGiC catheter, I mean, a lot of enhancements and capabilities. One, and it's exciting to hear about all the PFA development programs that are underway under your roof now, but are you going to ultimately pursue a high-power, short-duration energy delivery approach with MAGiC cath? I believe that you can get to 100 watts with MAGiC, but I guess J&J's having some success with QDOT. I just wanted to touch on that topic.
David Fischel: Sure. So high-power short duration radio frequency ablation is an exciting and interesting part of the EP landscape. We tested the MAGiC catheter through bench and preclinical testing up to 100 watts, and one of the beautiful features of the MAGiC catheter and the gold tip specifically is how stable the temperature of the tip stays even at very, very high powers. So usually, as you increase power, you run the risk of char and heating up of the tip, which can lead to coagulation and kind of other clinical risks. The tip of MAGiC stays extremely stable even at very high wattage, which is kind of, again, a beautiful kind of aspect. It's related to both the material of the tip and the way the irrigation flows through the tip, even when you have very low irrigation use, kind of reducing the fluid load that typically a patient is receiving during an ablation procedure. Catheters in the U.S. almost all radiofrequency ablation catheters, are approved only up to 50 watts from a power setting. And so we have only pursued -- in terms of the pivotal animal studies and what was submitted for a label, we pursued up to 50 watts. And so while the device is definitely built towards things beyond that and can accommodate powers beyond that, that's not part of the label that we're pursuing, and that won't be part of any initial device. And so I think kind of we'll have the opportunity to pursue higher power short duration post-approval. We can do additional studies, but we haven't been attempting to do that at this point. But even at 50 watts, we have a beautiful lesions that form overall in a very rapid fashion, so I think the performance of the catheter is very much in line with that evolution of the field.
Josh Jennings: Thanks for that. I'm sorry. One more in here, but I think you're going to get -- we're going to be able to -- your MAGNETIC VT study results, the Traverse data was presented as a late breaker at ACC. Just thinking about those two datasets, if they're positive and how that could benefit kind of your marketing to EP labs for the clinical value proposition for robotic magnetic navigation once those datasets are read or the MAGNETIC VT study is read out? Thanks a lot.
David Fischel: Yes, sure. So the MAGNETIC VT study was a prospective randomized study comparing robotics versus manual cardiac ablation for ischemic VT patients. We completed -- or well, we decided to stop enrollment early just because it was enrolling relatively slowly and it wasn't strategically critical to our path in terms of building this new product ecosystem. So we enrolled it. At the end of the day, it's probably actually the largest randomized prospective VT study that's out there in the ablation field. It's enrolled roughly 180 patients. All the patients finished their follow-up, and we've been working with statisticians and the PIs to get the results ready for a presentation at one of the upcoming conferences. So again, I'd expect that at one of the upcoming conferences, the PIs are going to present the results, and we'll do a concurrent release at the time.
Operator: Our next question comes from the line of Frank Takkinen with Lake Street Capital Markets. Please go ahead.
Nelson Cox: Hi. This is Nelson Cox on for Frank. Good to see all the progress, and congrats on the CE mark.
David Fischel: Thanks, Nelson.
Nelson Cox: I wanted to follow up on the earlier question on the manufacturing scale-up process for GenesisX. It sounds like confidence there is strong, but can you help us quantify the scale you will be able to build versus how that compares with Genesis and maybe how the timelines of production compare?
David Fischel: Sure. That's hard to do with specificity, given that we have only manufactured less than a handful of GenesisX systems to date, and we've not yet -- those have been manufactured largely by the R&D team rather than the dedicated manufacturing team. And so that is really part of this process over the next few months is how do you -- how do we make sure that it can be built by the manufacturing team directly in an efficient way? We know that we can build it reliably, but you want to kind of do all the little tricks and little processes that make it an efficient manufacturing process. Overall, in the past, we've talked about how the new headquarters that we established a couple of years ago that allowed us to manufacture in the tens of systems, let's say, the mid high tens of systems a year, in this facility, we would obviously have to scale our personnel as we go to those levels. But we can do -- we can manufacture roughly a system a month and have enough space to do more than four at a time. And so that's kind of -- that's one factor. I'd say with GenesisX, given that the systems do not have to be assembled facing each other and their -- again, the left and the right are identical to each other, you have definite efficiencies from a time, personnel, complexity perspective over Genesis. And so I don't know exactly where we're going to end up. But it's definitely, we can grow in order of magnitude from where we are right now in our current facility with the technologies we have, and I look forward to the challenges and problems of having to scale beyond that.
Nelson Cox: Perfect. That's great. And then with the CE mark and expected incoming FDA 510(k), it sounds like interest is strong. I guess one question there is will this cause hospitals to pause and wait for the next-generation system? Or is that not something you're really thinking about right now? Or any color there?
David Fischel: It's definitely a factor on our minds, and there is a little bit of that, that takes place and plays out. We did include it in the press release and the prepared remarks commentary about there being a late-stage pipeline of Genesis orders, Genesis systems, across three geographies. There is -- definitely, despite GenesisX, there are customers for whom Genesis is the most reasonable, best option, right? Imagine a hospital that already has a Niobe system wants to upgrade. They already have a lab that is shielded, that is reinforced, all of that kind of has already been built in. It just makes sense for them to get the Genesis robot. Doesn't make sense for them to wait for GenesisX. They've already done the construction work for it. So there are definitely labs like that where GenesisX won't cause any confusion or mix up or delays. There is an aspect of some of our greenfield pipeline wanting to wait for GenesisX, and I think that, that's kind of -- that's okay. We'll be able to -- we have enough clarity into our backlog of Genesis orders. We have enough clarity into our pipeline of newer term Genesis orders that can carry us through for the coming months. And then as GenesisX ramps up, in reality, that is an easier, again, product to scale from the organizational perspective. So I'm delighted. If customers decide that they ultimately want to choose GenesisX, we have no problem with that.
Nelson Cox: Perfect. And then maybe just one more quick one. I know a lot of it is construction timelines, but can you just walk us through at a high level, anything from a macro perspective in terms of capital equipment purchasing patterns or what you've seen there?
David Fischel: Sure. It's been asked sometimes in the past. I mean we feel like we're a tiny, tiny fish in a big ocean, and so whether the macro environment raises the tide a little bit, reduces the tide a little bit, to some extent, we're fighting our own fight, and it doesn't make a major difference for us. There's definitely some macro weakness, headwinds in China. There are kind of macro factors there that are making it difficult, not just for us, but we know all the other capital equipment companies. They have similar challenges now, and no one knows exactly when that's going to turn. But hopefully, by the time we are getting approval for the full ecosystem of robot catheter mapping system in China, it will be a better macro environment there. Despite that -- and again, even in bad macro environments, there still is always some opportunities, some purchasing. So we definitely have a pipeline of customers, real engaged customers, also in China. And in Europe and the U.S., I think that it's -- I don't sense any major changes to the overall environment. Since we started rebuilding a capital sales capability in 2020, it has been overall a macro headwind environment, right? We had the chaos of COVID, the chaos of personnel challenges where hospitals didn't have nurses, didn't have techs, were spending huge amounts to try to recruit and hire people just to run their daily operations. The macroeconomic environment hasn't been the easiest environment. So I think that's been kind of an overarching kind of reality since we restarted capital sales four years ago. And obviously, we've been able to make some headway despite that. So I think kind of we don't see things being particularly different, neither on the negative or the positive. If the environment changes where it's a macro tailwind environment, that will be awesome, but we're not betting on that. And to some extent, it's the things that we do in-house to make the -- to being the small fish in a very, very big ocean, becoming a stronger fish on our own that, to some extent, changes everything irrespective of whether the tides go up a few feet or down a few feet.
Nelson Cox: Great. Congrats again. Thanks, guys.
David Fischel: Thank you very much.
Operator: We have no further questions at this time. I will now turn the call back to David Fischel for closing remarks.
David Fischel: Okay. Thank you very much for your questions. We look forward to working hard on your behalf and speaking again next quarter. Thank you.
Operator: This will conclude today's conference call. Thank you all for your participation. You may now disconnect.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.